NeuroScientific Biopharmaceuticals: Launches post-COVID fibrosis research program -

NeuroScientific Biopharmaceuticals is teaming up with the Institute of Respiratory Health and the University of Western Australia to find a treatment for post-COVID fibrosis
Then the disease can cause lasting damage to the lungs, even in young adults, and could potentially become one of the largest future burdens on global healthcare
However, recent data has shown that a protein known as Metallothionein can protect the lungs from injury and fibrosis
This is where NSB comes in: its flagship candidate, EmtinB, designed to mimic the protein in patients
NSB and UWA’s will now research the protein and its viability as a post-COVID fibrosis treatment, with data set for release in the first half of 2021
On the market this afternoon, NSB remains steady and is trading for 34 cents per share

NeuroScientific Biopharmaceuticals: Launches post-COVID fibrosis research program